Introduction:
In Australia, colorectal cancer(CRC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related death¹. The liver is the most frequent site of metastasis and contributes significantly to morbidity and mortality, with a 5-year overall survival of just 25.2% for patients with liver-only metastases². Outcomes and access to care may differ in regional areas compared to the national average. There is limited data on how these patients are managed in Gippsland.
Aim:
This study aims to evaluate treatment patterns and clinical outcomes of patients with liver metastases secondary to colorectal cancer in Gippsland, and to identify opportunities to improve quality of care and promote equity in rural health.
Method:
A retrospective audit was conducted on patients with liver metastases from CRC discussed in the Skin, Upper GI and colorectal, and Advanced Disease multidisciplinary meeting (MDM) summaries from the Gippsland Cancer Care Centre, recorded in QOOL VIC, between January 2023 and December 2024. Descriptive statistics and comparative analyses will be used to evaluate patterns in treatment modalities and clinical outcomes.
Prelim Results:
Preliminary analysis of MDM summaries from 1,009 patients seen at the Gippsland Cancer Care Centre between 2023-2024 identified 46 patients with liver metastases secondary to CRC. Pre operative chemotherapy ranged from 3 to 6 months and consisted mainly of doublet and triplet regimens. Gippsland patients who had liver resections were performed at Monash Health and St Vincent’s. These patients also tend to be younger with a better performance status.
Data collection is ongoing to support further comparative analysis.
Discussion:
Local data will be compared to a recent published analysis from the TRACC clinical registry which comprises metropolitan and regional hospitals in Australia.